SABS

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

SAB Biotherapeutics Inc

NASDAQ | SABS

3.59

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$176.62M

Market Cap

-

P/E Ratio

-1.56

EPS

$4.99

52 Week High

$1.00

52 Week Low

HEALTHCARE

Sector

SABS Chart

Recent Chart
Price Action

SABS Technicals

Tags:

SABS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $1.3M
Cost Of Revenue $4.8M
Costof Goods And Services Sold $4.8M
Operating Income -$43M
Selling General And Administrative $14M
Research And Development $30M
Operating Expenses $39M
Investment Income Net -
Net Interest Income $968K
Interest Income $1.3M
Interest Expense $318K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $4.8M
Income Before Tax -$34M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$34M
Comprehensive Income Net Of Tax -
Ebit -$34M
Ebitda -$29M
Net Income -$34M

Revenue & Profitability

Earnings Performance

SABS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $44M
Total Current Assets $24M
Cash And Cash Equivalents At Carrying Value $8.9M
Cash And Short Term Investments $8.9M
Inventory -
Current Net Receivables $55K
Total Non Current Assets $20M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $12M
Other Current Assets $3M
Other Non Current Assets -
Total Liabilities $18M
Total Current Liabilities $8M
Current Accounts Payable $1.7M
Deferred Revenue -
Current Debt -
Short Term Debt $812K
Total Non Current Liabilities $10M
Capital Lease Obligations $4.4M
Long Term Debt -
Current Long Term Debt $276K
Long Term Debt Noncurrent -
Short Long Term Debt Total $4.7M
Other Current Liabilities $5.5M
Other Non Current Liabilities -
Total Shareholder Equity $26M
Treasury Stock -
Retained Earnings -$124M
Common Stock $935
Common Stock Shares Outstanding $9.3M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$34M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $4.8M
Capital Expenditures $337K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$12M
Cashflow From Financing -$1.2M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$34M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $1.3M
Cost Of Revenue $4.8M
Costof Goods And Services Sold $4.8M
Operating Income -$43M
Selling General And Administrative $14M
Research And Development $30M
Operating Expenses $39M
Investment Income Net -
Net Interest Income $968K
Interest Income $1.3M
Interest Expense $318K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $4.8M
Income Before Tax -$34M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$34M
Comprehensive Income Net Of Tax -
Ebit -$34M
Ebitda -$29M
Net Income -$34M

SABS Profile

SAB Biotherapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

SAB Biotherapeutics Inc. is a pioneering biopharmaceutical firm dedicated to developing advanced immunotherapies for infectious diseases, autoimmune disorders, and oncology. Based in Sioux Falls, South Dakota, with a significant presence in Cambridge, Massachusetts, the company employs its proprietary technology platform to generate fully human therapeutic antibodies from genetically engineered cows. This innovative approach enables SAB Biotherapeutics to tackle critical health challenges and deliver novel therapeutic solutions in areas with substantial unmet medical needs, solidifying its role as a leader in the biotherapeutics sector.

ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.52%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
TSLA
-1.01%
$446.89
KVUE
0.00%
$17.32
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
K
-0.01%
$83.44
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
WBD
-0.13%
$29.49
BTG
0.00%
$4.68
RR
+12.77%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
T
-0.36%
$24.30
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
NIO
+1.98%
$5.13
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
SRM
+53.27%
$10.30
PFE
+0.07%
$25.80
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RIG
-0.46%
$4.28
RKLB
+10.44%
$63.53
JBLU
-2.78%
$4.89
QBTS
+4.40%
$27.98
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
SNAP
-3.53%
$7.64
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
NCLH
+6.80%
$20.55
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
KO
-1.56%
$69.11
SMCI
-2.52%
$34.02
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
UBER
+1.52%
$85.44
CNQ
-1.72%
$33.14
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82
ATPC
+164.70%
$0.18
LPTX
+368.57%
$2.05
NVDA
-1.55%
$180.93
WOK
-11.52%
$0.16
PAVS
-9.21%
$0.03
VSME
+11.42%
$0.09
PETS
+68.36%
$2.98
RZLT
-87.20%
$1.40
YGMZ
-61.42%
$0.02
PLUG
+4.42%
$2.36
ORCL
-10.83%
$198.85
RIVN
-6.11%
$16.43
ASST
-7.82%
$0.92
VIVK
+14.55%
$0.07
URG
-8.08%
$1.25
KIND
+9.48%
$2.77
NXDR
+9.48%
$2.77
AXDX
-61.36%
$0.03
IVP
-12.52%
$0.05
ONDS
+8.34%
$9.02
IRBT
-4.58%
$5.00
INTC
-3.11%
$39.51
F
+1.64%
$13.63
MIGI
-8.95%
$6.10
TSLA
-1.01%
$446.89
KVUE
0.00%
$17.32
BTTC
+24.28%
$4.12
ADAP
-15.14%
$0.05
DNN
+2.60%
$2.76
AAL
-1.18%
$14.96
AVGO
-1.59%
$406.37
HOOD
-9.05%
$123.38
MARA
-0.67%
$11.84
NFLX
+1.48%
$94.09
TE
-4.55%
$5.87
K
-0.01%
$83.44
SOND
-23.45%
$0.12
GOOGL
-2.42%
$312.43
SOFI
-0.07%
$27.07
BMNR
-5.00%
$38.38
WBD
-0.13%
$29.49
BTG
0.00%
$4.68
RR
+12.77%
$4.68
VALE
+2.30%
$13.29
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
T
-0.36%
$24.30
RGTI
+2.90%
$26.88
BYND
-4.06%
$1.18
ADD
-25.47%
$0.05
NIO
+1.98%
$5.13
PLTR
-0.19%
$187.54
BAC
+0.88%
$54.56
SRM
+53.27%
$10.30
PFE
+0.07%
$25.80
HL
+12.56%
$19.35
ASBP
+22.50%
$0.10
PLTD
+0.15%
$6.32
AAPL
-0.26%
$278.03
GRAB
0.00%
$5.18
BITF
0.00%
$2.94
HPE
-2.85%
$24.54
RIG
-0.46%
$4.28
RKLB
+10.44%
$63.53
JBLU
-2.78%
$4.89
QBTS
+4.40%
$27.98
AMD
+0.00%
$221.43
BMNU
-10.03%
$10.22
CIFR
+2.16%
$18.88
NGD
+9.19%
$8.55
ACHR
+2.27%
$8.56
AG
+7.13%
$16.81
CDE
+9.45%
$17.48
AMZN
-0.64%
$230.28
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
BTBT
+4.23%
$2.46
SNAP
-3.53%
$7.64
CRWV
-0.88%
$87.38
IREN
+0.04%
$43.94
NCLH
+6.80%
$20.55
ABEV
+2.04%
$2.50
FI
+2.38%
$68.16
GOOG
-2.27%
$313.70
NOK
+2.25%
$6.36
MSFT
+1.02%
$483.47
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
PCG
-1.65%
$14.83
AFMD
-34.94%
$0.18
KO
-1.56%
$69.11
SMCI
-2.52%
$34.02
WULF
+0.44%
$15.83
LUV
+2.28%
$40.74
UBER
+1.52%
$85.44
CNQ
-1.72%
$33.14
SOUN
-1.47%
$12.03
SMR
+4.42%
$21.22
CHR
-5.72%
$0.04
CLSK
+1.99%
$14.82
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.